| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/19/2004 | WO2004069231A1 Transdermal therapeutic system with improved adhesion to the skin |
| 08/19/2004 | WO2004069230A1 Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion |
| 08/19/2004 | WO2004069229A1 Dual release anti-diabetic drugs and process of production thereof |
| 08/19/2004 | WO2004069228A2 Sustained release formulations of venlafaxine |
| 08/19/2004 | WO2004069227A1 Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides |
| 08/19/2004 | WO2004069226A1 Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides |
| 08/19/2004 | WO2004069225A1 Novel fluticasone formulations |
| 08/19/2004 | WO2004069224A2 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs |
| 08/19/2004 | WO2004069223A2 Pharmaceutical compositions comprising immunosuppressants and uses thereof |
| 08/19/2004 | WO2004069203A2 Oral compositions of fenretinide having increased bioavailability and methods of using the same |
| 08/19/2004 | WO2004069198A2 Sugar-free oral transmucosal solid dosage forms and uses thereof |
| 08/19/2004 | WO2004069187A2 Drug formulation and delivery using crystalline methylated cyclodextrins |
| 08/19/2004 | WO2004069180A2 Solid dispersion compositions |
| 08/19/2004 | WO2004069179A2 Improved thickened beverages for dysphagia |
| 08/19/2004 | WO2004069169A2 Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same |
| 08/19/2004 | WO2004069156A2 Inactivated probiotic bacteria and methods of use thereof |
| 08/19/2004 | WO2004069141A2 Transdermal granisetron |
| 08/19/2004 | WO2004069138A2 Pharmaceutical formulation |
| 08/19/2004 | WO2004069135A2 Composition comprising a mixture of active principles, and method of preparation |
| 08/19/2004 | WO2004069134A2 Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology |
| 08/19/2004 | WO2004069132A2 Pharmaceutical preparations and a method for their production |
| 08/19/2004 | WO2004069095A2 Remote multi-purpose user interface for a healthcare system |
| 08/19/2004 | WO2004069032A2 Viscous swallow medium and method of use for esophageal function testing |
| 08/19/2004 | WO2004057950A3 Liposomal analgesic formulation and use |
| 08/19/2004 | WO2004056337A3 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| 08/19/2004 | WO2004054356A3 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 08/19/2004 | WO2004047839A8 High concentration formulations of opioids and opioid derivatives |
| 08/19/2004 | WO2004047801A3 Method of drug loading in liposomes by gradient |
| 08/19/2004 | WO2004047729A3 Composition for the prevention and treatment of inflammation of the ear |
| 08/19/2004 | WO2004043388A3 Chewing gum with encapsulated stain removing agent |
| 08/19/2004 | WO2004041195A3 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 08/19/2004 | WO2004039323A3 Fast curing compositions |
| 08/19/2004 | WO2004034876A3 Magnetically guided particles for radiative therapies |
| 08/19/2004 | WO2004026281A3 Micro-reservoir osmotic release systems and microtube array device |
| 08/19/2004 | WO2004019912A3 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 08/19/2004 | WO2004019853B1 Dosage forms having reduced moisture transmission |
| 08/19/2004 | WO2003092585A3 Controlled release compositions of estradiol metabolites |
| 08/19/2004 | WO2003077834A3 Central airway administration for systemic delivery of therapeutics |
| 08/19/2004 | WO2003034999A3 Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers |
| 08/19/2004 | WO2002089778A3 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| 08/19/2004 | US20040162580 Sutures and coatings made from therapeutic absorbable glass |
| 08/19/2004 | US20040162518 Constant rate fluid delivery device with selectable flow rate and titratable bolus button |
| 08/19/2004 | US20040162355 Methods of treating and preventing cerebral function disorders using sibutramine metabolites |
| 08/19/2004 | US20040162349 Use of polyunsaturated fatty acid for the primary prevention of major cardiovascular events |
| 08/19/2004 | US20040162344 Effective ingredient and basic agent; foam suppression |
| 08/19/2004 | US20040162336 containing alcohol, water and a glycol; rapid drug delivery; bioavailability |
| 08/19/2004 | US20040162333 Rapid absorption selective 5-HT agonist formulations |
| 08/19/2004 | US20040162320 Dissolution profiles which can be adjusted in a range from slow to fast release according to the effect targeted for the clinical trials |
| 08/19/2004 | US20040162275 Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer |
| 08/19/2004 | US20040162273 Powder pharmaceutical compositions |
| 08/19/2004 | US20040162272 Chemical enhancer and method |
| 08/19/2004 | US20040162268 Extracted portion of psyllium seed with a binder and/or edible acid; polysaccharide component comprising xylose and arabinose in given ratio; specified mean particle size distribution; use for therapy of gastrointestinal disorders, as laxative |
| 08/19/2004 | US20040162267 Compositions comprising a polysaccharide component and one or more coating layers |
| 08/19/2004 | US20040162266 Compositions comprising a defined polysaccharide component |
| 08/19/2004 | US20040162264 Methods, pharmaceutical and therapeutic compositions for administering adenosine |
| 08/19/2004 | US20040162263 Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| 08/19/2004 | US20040162261 Double chain compound having an amino group and a carboxyl group in the hydrophilic part; forms a stable bilayer membrane vesicle in water, and a water-soluble drug can be enclosed in the internal phase of the vesicle at high efficiency |
| 08/19/2004 | US20040162259 Administering oligonucleotide targeted to human ICAM-1 mRNA for therapy |
| 08/19/2004 | US20040162257 For inhibiting angiogenesis |
| 08/19/2004 | US20040162256 Method for producing sterile polynucleotide based medicaments |
| 08/19/2004 | US20040162255 To deliver specifically tailored small interfering RNA as therapeutic agents for treatment of Parkinson's disease |
| 08/19/2004 | US20040162254 Antiviral oligonucleotides targeting HSV and CMV |
| 08/19/2004 | US20040162253 Administering pharmacologically acceptable oligonucleotide at least 10 nucleotides in length, wherein the anti-HBV activity of oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 08/19/2004 | US20040162251 Pharmaceutical composition containing decoy and method of using the same |
| 08/19/2004 | US20040162235 Forming a complex of polyampholyte and siRNA; and, delivering the complex into a cell |
| 08/19/2004 | US20040161830 Spherical microparticles containing linear polysaccharides |
| 08/19/2004 | US20040161527 Drug encapsulated with vacuum formed film |
| 08/19/2004 | US20040161498 Production of capsules and particles for improvement of food products |
| 08/19/2004 | US20040161476 Aqueous solution; bladder and urogenital disorders |
| 08/19/2004 | US20040161475 Anticancer, antitumor agents; ssynergistic mixtures with retinoic acid; olid tumors |
| 08/19/2004 | US20040161471 Extraction psyllium seeds from polysaccharide binder ; gastrointestinal disorders |
| 08/19/2004 | US20040161470 Encapsulation of active material in polyphosphazenes |
| 08/19/2004 | US20040161469 Reduce concentration of solvent; cycles of washing, filtration |
| 08/19/2004 | US20040161467 Particulate drug-containing products and method of manufacture |
| 08/19/2004 | US20040161466 Chemoembolisation |
| 08/19/2004 | US20040161464 Polymeric formulations for drug delivery |
| 08/19/2004 | US20040161462 Sustained release; hypoglycemic agents; synergistic mixture |
| 08/19/2004 | US20040161461 Extended release pharmaceutical tablet of metformin |
| 08/19/2004 | US20040161460 Enteric coated formulation for bisphosphonic acids and salts thereof |
| 08/19/2004 | US20040161459 Milling, controlling particle size; hardness, brittleness ; blending with compactable filler and water absorbent material; freeze drying; compression |
| 08/19/2004 | US20040161458 Hard gelatin capsule containing mixture of surfactants |
| 08/19/2004 | US20040161457 Method of administering a compound to multi-drug resistant cells |
| 08/19/2004 | US20040161456 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes |
| 08/19/2004 | US20040161455 Method for treating multi-drug resistant tumors |
| 08/19/2004 | US20040161454 Economical; controlled delivery, self adhesive material |
| 08/19/2004 | US20040161452 Fluid impermeable, elastic dressing with refillable adsorbant pad that fits snuggly over finger or toe nail; sustained delivery of antimycotic agent |
| 08/19/2004 | US20040161451 Soft filament occlusive device delivery system |
| 08/19/2004 | US20040161447 Controlling surfactant and water content; consistent, dependable, repeatable; usable in variety of containers |
| 08/19/2004 | US20040161446 Employing biodegradable barrier having binding member that couples with cells or organ surface to hinder diffusion; sustained release, lower dosage |
| 08/19/2004 | US20040161441 Containing permethrin, imidacloprid and n-methylpyrrolidone; killing ticks and fleas; skin friendly, low toxicity; storage stability |
| 08/19/2004 | US20040161434 Nonaqueous liquid; acceptable taste; diluting in aqueous diluent for oral administration |
| 08/19/2004 | US20040161422 Nutritional compositions comprising probiotics |
| 08/19/2004 | US20040161411 Antibacterial therapy with bacteriophage genotypically modified to delay inactiovation by the host defense system |
| 08/19/2004 | US20040161407 Medicinal compositions |
| 08/19/2004 | US20040161403 Applicable for water insoluble, hydrophilic and charge bearing bioactive agents; controlled release |
| 08/19/2004 | US20040161392 Using salicylic acid derivative; side effect reduction |
| 08/19/2004 | US20040161386 Pharmaceutical compositions based on anticholinergic and dopamine agonists |
| 08/19/2004 | US20040161385 Delivery of beta-blockers through an inhalation route |
| 08/19/2004 | US20040161382 Oral drug delivery system |
| 08/19/2004 | US20040159322 Capsule for taking an active substance which can be inhaled |